Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

Corporate News

YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Corporate News

REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).

Qkine announces partnership with REPROCELL

Corporate News

Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture Cambridge, UK and Yokohama, Japan – Qkine Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, and REPROCELL Inc., Japan’s first and leading induced pluripotent stem cell (iPSC) company, have partnered to globally…

Bioserve India Launches Advanced Stem Cell Products in India

Corporate News

Hyderabad, India – 22nd July 2024 – Bioserve India is excited to announce the launch of its advanced stem cell products in India. These new products from REPROCELL aims to support innovation in scientific research and drug development, supporting advancements in regenerative medicine and therapeutic discovery in Indian Market. The stem cell market is a rapidly growing industry that encompasses a wide range of services and products. Within the stem cell market, numerous industries are engaged in critical activities such as research and development manufacturing, and distribution of stem cell therapy products.

Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar

Corporate News

Hyderabad, India and Doha, Qatar – May 6, 2024 – Bioserve Biotechnologies (India) Private Limited, a leader in molecular biology products, is excited to announce a new distributorship agreement with RISVI Trading W.L.L., a renowned trading company based in Doha, Qatar. This strategic partnership will enable Bioserve to expand its distribution network for molecular biology products, including DNA oligonucleotide synthesis in Qatar.